SCHEMBL15529465

SCHEMBL15529465

CC(C)(C)OC(=O)N1CCC(c2ccc(NC(=O)N3CC(c4cccnn4)C3)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 7/20 0.65
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
PTPN6 P29350 1/20 0.47
MAPT P10636 5/20 0.46
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
TP53 P04637 3/20 0.46
TSHR P16473 1/20 0.46
JAK2 O60674 2/20 0.45
JAK3 P52333 2/20 0.45
PTK2 Q05397 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
ABL1 P00519 1/20 0.44
RIN1 Q13671 1/20 0.44
STAT1 P42224 1/20 0.44
LMNA P02545 1/20 0.44
NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15529486 0.88 NAMPT (0.54) NAMPTMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15529309 0.88 NAMPT (0.49) NAMPTPTPN2PTPN1PTPN6MAPT
SCHEMBL15529963 0.86 NPC1 (0.51) NAMPTMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15529176 0.85 NAMPT (0.56) NAMPTMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15529056 0.84 NAMPT (0.66) NAMPTPTPN2PTPN1PTPN6NPC1
SCHEMBL15530675 0.84 NAMPT (0.63) NAMPTPTPN2PTPN1PTPN6MAPT
SCHEMBL15529504 0.84 NAMPT (0.54) NAMPTMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15529190 0.83 NAMPT (0.64) NAMPTMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15529654 0.83 NAMPT (0.53) NAMPTMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15528730 0.82 NAMPT (0.64) NAMPTPTPN2PTPN1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758511-B2 NAMPT inhibitors ABBVIE INC. (US) 2017-09-12 US disclosed
US-20160168134-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-16 US disclosed
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US disclosed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP disclosed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US disclosed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168134-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT NAMPT 1/4885PTPN2 3985/4885PTPN1 4215/4885
US-20140336168-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT NAMPT 1/4885PTPN2 3985/4885PTPN1 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.